Stockwinners Market Radar for April 16, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:06 EDT Allegiant Travel flight attendants vote to approve new labor contract - Allegiant "announced that the company and the Transport Workers Union of America, AFL-CIO Local 577, representing Allegiant's flight attendants, have ratified a new five-year agreement with immediate wage increases ranging from 20 to 41.2 percent. The tentative agreement was ratified by Allegiant flight attendants with a 89 percent approval vote and 97 percent of members voting. The TWU Local 577 represents more than 1,700 Allegiant flight attendants."

19:50 EDT Sunshine Biopharma Inc trading halted, news pending

18:41 EDT Rio Tinto backs FY24 Pilbara iron ore output outlook of 323-338Mt - Backs FY24 Bauxite production view at 53-56 Mt, Aluminum production at 3.2-3.4Mt, Mined Copper production at 660-720kt.

18:33 EDT BrainStorm promotes Bob Dagher to Chief Medical Officer - BrainStorm Cell Therapeutics announced the promotion of Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prepares to embark on a registrational Phase 3b trial for NurOwn(R), its investigational cell therapy treatment for amyotrophic lateral sclerosis, or ALS. Dagher has served as our Chief Development Officer since July 2023. In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn. The Company recently announced that it has reached agreement with the FDA for a Special Protocol Assessment for this trial.

18:30 EDT Screaming Eagle Acquisition announces effectiveness of registration statement - Screaming Eagle Acquisition (SCRM) announced that the registration statement on Form S-4, filed by Screaming Eagle's wholly-owned subsidiary, SEAC II Corp., relating to the previously announced business combination with Lionsgate (LGF.A, LGF.B), has been declared effective by the U.S. SEC. The extraordinary general meetings of Screaming Eagle's shareholders and public warrant holders in connection with the Business Combination will be held on May 7. The proxy statement/prospectus relating to the Extraordinary General Meetings will be mailed to Screaming Eagle's shareholders and public warrant holders of record as of the close of business on April 16. As previously disclosed, on April 11, Screaming Eagle and Lionsgate entered into an additional PIPE subscription agreement for $50M, bringing the total committed PIPE financing in connection with the Business Combination to $225M. The parties anticipate that the Business Combination will close in early May, subject to satisfaction of the conditions to the closing of the Business Combination.

17:28 EDT Amgen to present Tezspire Phase 2a COPD data at ATS 2024 - Amgen "provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE(R) in chronic obstructive pulmonary disease, or COPD, which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. We are encouraged by the results of the COURSE Phase 2a proof-of-concept trial, which investigated tezepelumab in moderate to very severe COPD patients, across a broad range of eosinophil levels, irrespective of inflammatory drivers, emphysema, chronic bronchitis and smoking status. This study did not exclude any patients based on their baseline eosinophil count (BEC) and intentionally enrolled patients with a broad range of BECs. Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: -6, 36; p=0.1042). Of note, more reductions were observed in a prespecified subgroup of patients with BEC greater than or equal to150 cells/muL (37% [95% CI: 7, 57]). The trend in reduction was greater in a small number of subjects with BEC greater than or equal to300 cells/microL."

17:03 EDT Galiano Gold sees Asanko Gold Mine production 140,000-160,000 ounces - Galiano Gold provided 2024 operating and cost guidance and an update on the improved Abore Mineral Resource at the Company's Asanko Gold Mine located in Ghana, West Africa. The AGM is expected to produce 140,000-160,000 ounces at forecast All-In Sustaining Cost, or AISC, of between $1,600/oz to $1,750/oz. With the AGM now owned 90% by Galiano, production is expected to significantly exceed that of 2023, more than doubling the Company's attributable gold production. AISC1 is anticipated to be slightly elevated in 2024 primarily due to the waste stripping to access consistent ore feed at Abore, which will benefit future years production. Sustaining capital, exclusive of capitalized waste stripping, is expected to be approximately $10M in 2024. Growth capital in 2024 is expected to be approximately $20M and primarily includes plant upgrades and site establishment costs. The exploration program in 2024 is expected to be in line with previous years at $15M. The spend is planned to be equally split between generative and near-mine exploration activities.

16:40 EDT Autodesk down 4% at $219.92 after issuing update on delayed Form 10-K filing

16:34 EDT PaxMedica announces request from MOH for emergency access to IV suramin - PaxMedica announced it has received an urgent request from the Ministry of Health, or MOH, of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa. PaxMedica, which just last week announced that it has completed execution of its three pivotal registration/validation batches of PAX-101, an IV form of suramin, has brought this emergency request to the attention of the FDA to determine potential impact, if any, on the ongoing development program and NDA submission plans for PAX-101. PaxMedica has previously announced the completion of its recent Type B meeting with FDA in preparation for submitting an NDA for the use of PAX-101 in the treatment of the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, caused by the bite of a tsetse fly. The company said, "PaxMedica is in the process of responding to the Malawi Ministry of Health's request and is in contact with regulatory authorities in both the U.S. and Malawi with an intention to help with today's emergency, as well as to work with the FDA to determine the best path forward to submit the PAX-101 NDA for regulatory approval, as well as to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide PaxMedica resources to help ensure a steady supply of suramin to these endemic regions."

16:28 EDT Zapp announces 1-for-20 reverse stock split - Zapp Electric Vehicles Group owner of "Zapp", the British electric vehicle brand on a mission to revolutionize personal urban mobility, today announced that its shareholders approved at the Company's annual general meeting on April 11 and that the Company will effect, a consolidation of its authorized share capital at a ratio of 1-for-20...

16:23 EDT Omega Therapeutics CFO Joshua Reed to depart - On April 10, 2024, Omega Therapeutics and Joshua Reed, the company's CFO, agreed to terminate his employment effective as of May 31, 2024. In connection with the termination, Mr. Reed will be entitled to receive the severance payments and benefits set forth in his employment agreement with the Company and extended exercisability of his exercisable Company stock options until the first anniversary of the Effective Date, in each case, subject to his entering into a separation agreement containing a release of claims. On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company's Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.

16:22 EDT Clene presents VISIONARY-MS long term extension study results - Clene presented the Phase 2 VISIONARY-MS long term extension, or LTE, study results at the 2024 American Academy of Neurology, or AAN, annual meeting in Denver. Michael Barnett from the University of Sydney presented data demonstrating improved clinical, functional, and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg for up to three years of treatment. These new long-term results from the Phase 2 VISIONARY-MS clinical trial demonstrated evidence supporting repair and remyelinating effects of CNM-Au8 treatment in patients originally randomized to CNM-Au8. The long-term results further enhance the trial's findings from the double-blind period, which demonstrated significant improvements on low contrast letter acuity and on the modified MS Functional Rating Scale, the study's primary and secondary endpoints, with continued improvement observed in the LTE. The significant and concordant results across multiple paraclinical exploratory endpoints reinforce the evidence for sustained clinical benefit to study participants across multiple clinical outcome measures, associated with consistent improvements in neuronal function and remyelination. Participants originally randomized to CNM-Au8 treatment experienced continued significant improvement in vision as measured by low contrast letter acuity. More than half of participants improved by 10 or more letters on a low-contrast Sloan eye chart, with increases of up to 38 letters. Participants originally randomized to placebo who transitioned to CNM-Au8 after the 48-week double blind period into the open label extension also experienced significant improvement in vision as measured by low contrast letter acuity following treatment with 30 mg CNM-Au8. Study participants treated with CNM-Au8 experienced up to 29 points of significant improvement in cognition and working memory as measured by the Symbol Digit Modality Test. Study participants treated with CNM-Au8 experienced significant improvements in both amplitude and latency as measured by multi-focal visual evoked potentials, physiologic measures of signal strength and speed along the visual pathway, markers of neuronal health and remyelination, respectively. MRI measures of axial diffusivity showed significant improvements in T2 brain lesions in study participants treated with CNM-Au8. MRI measures of T2 lesion myelin water fraction and magnetization transfer ratio, markers of remyelination, improved with long-term CNM-Au8 treatment. CNM-Au8 was well-tolerated, and no significant safety findings were observed.

16:16 EDT Alamo Group receives notification of strike at Gradall subsidiary - Alamo Group was notified on April 14 that the unionized workers at its subsidiary, Gradall Industries located in New Philadelphia, Ohio, elected to strike after failing to reach a labor agreement with the Company. The approximately 200 workers are part of the International Association of Machinists and Aerospace Workers, District Lodge 54, Local Lodge 1285. Negotiations are ongoing and the Company is committed to working in good faith with union leaders to reach agreement on the new labor agreement and restore normal operations.

16:13 EDT Omnicell announces XT Amplify - Omnicell announced XT Amplify, a multi-year innovation program that is intended to maximize value for hospitals, health systems, and post-acute care facilities that have invested in Omnicell's XT Automated Dispensing System while also seeking to drive enhanced clinical and operational outcomes at the points of care and within pharmacies. "We recognize that some of our customers are navigating difficult operational and economic environments. We believe Omnicell is nicely positioned to address these current challenges while adapting for the future," said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. "We are confident the XT Amplify program will deliver continuous innovation that addresses these evolving and complex needs, while helping customers to maximize outcomes and the value of Omnicell automated dispensing systems currently in use around the globe."

16:11 EDT HubSpot announces departure of Chief Customer Officer Rob Giglio - The company "announced that Rob Giglio has stepped down from his role as Chief Customer Officer and has left the Company as of Friday, April 12, 2024. The Company will not be filling the Chief Customer Officer role and has promoted the current leaders of sales, marketing, and customer success to report directly to HubSpot's Chief Executive Officer, Yamini Rangan. Christian Kinnear will continue as Chief Sales Officer, a role he has held for over two years. In his nine years at HubSpot, Christian has held several international sales leadership roles and brings a global perspective to the discipline. Kipp Bodnar will continue as Chief Marketing Officer, a role he has held for nearly nine years. A thought leader in the application of artificial intelligence to go-to-market, Kipp brings unique insights on how HubSpot can lead the way for customers with AI. Jon Dick, who was recently appointed to lead customer success after eight years within HubSpot's marketing organization, deeply understands the full customer journey and is a champion for deeper alignment across teams. Together, these three leaders have driven transformational growth for HubSpot in their collective tenure."

16:11 EDT United Airlines up 6% to $43.94 after Q1 results beat estimates

16:09 EDT J.B. Hunt reports Q1 Dedicated Contract Services segment revenue $860M, down 2% - The company states: "DCS revenue decreased 2% during the current quarter over the same period 2023, driven by a 1% decline in average trucks combined with a 1% decline in productivity (gross revenue per truck per week). Productivity excluding fuel surcharge revenue increased 1% from a year ago driven by contracted indexed-based price escalators, partially offset by an increase in idled equipment. On a net basis, there were 71 fewer revenue producing trucks in the fleet by the end of the quarter compared to the prior-year period, and 2 more versus the end of the fourth quarter 2023. Customer retention rates are approximately 91%, largely reflecting the downsizing of fleets and to a lesser extent account losses."

16:07 EDT Autodesk provides update on internal investigation - Autodesk provided an update on the previously reported internal investigation that is currently being conducted by the Audit Committee of the Board of Directors of the Company. As described in the Company's Form 12b-25 Notification of Late Filing filed with the SEC on April 1 the Committee commenced an internal investigation with the assistance of outside counsel and advisors regarding the Company's free cash flow and non-GAAP operating margin practices. The subject of the internal investigation remains the same as previously disclosed, and the Company currently does not believe that any of the matters under investigation affect any previously issued financial statements or the information in the Company's earnings release on February 29, 2024. As of today, the investigation is ongoing and all parties continue to work diligently to complete the investigation. The Company will not file its Annual Report on Form 10-K for the year ended January 31 within the 15-day extension period contemplated by Rule 12b-25 under the Securities Exchange Act of 1934, as amended, due to the ongoing investigation. Accordingly, the Company expects to receive a notice from The Nasdaq Stock Market that it is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250. Such notification letter is not expected to have an immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market.

16:03 EDT United Airlines reports Q1 capacity up 9.1% y/y

16:02 EDT CareDx names John Hanna as new CEO - CareDx has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. Hanna brings to CareDx over two decades of executive leadership at the intersection of new technology development and revenue growth in the molecular diagnostics and life sciences tools industries.

16:01 EDT United Airlines reports Q1 TRASM up 0.6% y/y - Reports Q1 CASM down 0.6%, and CASM-ex up 4.7%, compared to first-quarter 2023.

14:32 EDT Envestnet up 14% after report on company exploring sale - Shares of Envestnet are up $7.91, or 14%, to $64.45 following Reuters' report.

12:20 EDT Crocs rehires Stanley's Terence Reilly as HeyDude president - Crocs earlier today announced the appointment of Terence Reilly as incoming executive vice president and president for the HeyDude Brand. Reilly, 56, most recently served as the President of the Stanley Brand. Prior to his time at Stanley, Reilly served as the Chief Marketing Officer at Crocs. Reilly succeeds Rick Blackshaw, who is leaving the company effective immediately. Reilly will join the executive leadership team on April 29.

12:00 EDT Annovis Bio falls -9.6% - Annovis Bio is down -9.6%, or -$1.06 to $10.03.

12:00 EDT Skillsoft falls -32.6% - Skillsoft is down -32.6%, or -$3.00 to $6.20.

12:00 EDT North European Oil Royalty Trust rises 8.4% - North European Oil Royalty Trust is up 8.4%, or 54c to $6.99.

10:51 EDT SilverBow sinks after largest holder Kimmeridge drops buyout proposal - Kimmeridge, the largest shareholder of SilverBow Resources holding 12.9% of outstanding shares, earlier today withdrew its proposal to acquire SilverBow. Kimmeridge said in a statement: "It appears that SilverBow is not willing to seriously engage in any discussions of mergers in which it would be the smaller party. Instead, the Board and management team are focused on maintaining their positions and compensation. Given SilverBow's lack of engagement, Kimmeridge sees no pathway towards a transaction by the April 26, 2024 deadline that we had put forward more than a month ago. As a result, we are withdrawing the Proposal and will be focused on providing solutions for SilverBow's broken governance. The only way SilverBow will maximize value for all shareholders and reach its long-term potential is by introducing new, independent, and experienced perspectives to the Board. The nominees we have put forward are committed to conducting a thorough and unbiased evaluation of all potential paths to value creation - and are bound by none of them, including our prior Proposal. Their only fiduciary duty is to advance the best interests of all SilverBow shareholders." Shares of SilverBow are down 5%, or $1.49, to $30.85 in morning trading.

10:07 EDT Pearson awarded U.K. government contract for England's NCA tests - Pearson has been selected by the U.K. Department for Education's Standards and Testing Agency to manage the administration, processing and support for all primary school national curriculum assessment tests in England. The contract runs for four years beginning from the academic year 2025/26. Pearson will deliver services to 16,500+ primary schools across the country for optional end of KS1 national curriculum assessments, the end of KS2 national curriculum tests and teacher assessments in English writing and science, as well as the phonics screening check.

10:04 EDT PNC Financial says "positioned well" for balance of 2024, beyond - Says executed well, delivered solid financial results. Says continued to grow business. Says expenses were well managed. Says credit quality remains stable. Comments taken from Q1 earnings conference call.

10:00 EDT Azul falls -8.8% - Azul is down -8.8%, or -55c to $5.71.

10:00 EDT Skillsoft falls -17.7% - Skillsoft is down -17.7%, or -$1.63 to $7.57.

10:00 EDT UnitedHealth rises 6.3% - UnitedHealth is up 6.3%, or $27.86 to $473.49.

09:59 EDT Better Choice Company trading halted, volatility trading pause

09:49 EDT UnitedHealth says experienced more complex quarter - Says recovering quickly from cyber attack. Says sees healthcare environment in need of improvement. Says inflation up year-over-year. Says saw increases in SpecialtyRx. Says Optum has been incredibly consistent. Says member engagement is incredibly important. Says feels good about ability to control utilization on medical side. Says specialty trends is a focus on pharmacy side. Comments taken from Q1 earnings conference call.

09:47 EDT Live Nation falls -8.2% - Live Nation is down -8.2%, or -$8.17 to $91.60.

09:47 EDT Global Blue rises 5.6% - Global Blue is up 5.6%, or 27c to $5.14.

09:47 EDT Auna rises 7.2% - Auna is up 7.2%, or 54c to $8.05.

09:46 EDT International Game, Acres resolve all pending litigation, no terms disclosed - International Game Technology and Acres 4.0, Acres Manufacturing Company, and John Acres, announced that effective April 16, they have reached an agreement to resolve all legal disputes between the two companies. Terms of the settlement have not been announced. The resolution was reached in the United States District Court of Nevada, directed to United States patents that pertain to facilitating use of a financial transaction device in a cashless wagering system in a gaming system, and Nevada State Court directed to a breach of contract claims.

09:35 EDT Barnes & Noble Education to receive $95M of new capital - Barnes & Noble Education (BNED) announced that it has entered into a definitive agreement with Immersion Corporation (IMMR) and certain of the company's existing shareholders and strategic partners, on the terms of new equity and refinancing transactions that will strengthen BNED's long-term financial position. Upon close, which is expected in June 2024: BNED will receive gross proceeds of $95M of new equity capital through a $50M new equity investment led by Immersion and a $45M fully backstopped equity rights offering; the transactions are expected to infuse approximately $75M of net cash proceeds after transaction costs. The company's existing second lien lenders, affiliates of Fanatics, Lids, and VitalSource Technologies, will convert approximately $34M of outstanding principal and any accrued and unpaid interest into BNED common stock; and the company has received commitments to refinance its existing asset backed loan facility, pursuant to an agreement with its first lien holders, providing the company with access to a $325M facility maturing in 2028. The refinanced ABL Facility will meaningfully enhance BNED's financial flexibility and reduce its annual interest expense. Through the Rights Offering, BNED plans to issue up to 900,000,000 shares of its Common Stock at a cash subscription price of 5c per share. In the Rights Offering, BNED will distribute to each holder of its Common Stock on the record date one non-transferable Right, for every share of Common Stock owned by such holder on the record date, and each Subscription Right will entitle the holder to purchase the number of shares of Common Stock determined by dividing 900,000,000 by the total number of shares of Common Stock outstanding on the record date. Each holder that fully exercises their Subscription Rights will be entitled to Over-Subscription Rights to subscribe for additional shares of Common Stock that remain unsubscribed as a result of any unexercised Subscription Rights, which allows such holder to subscribe for additional shares of Common Stock up to the number of shares purchased under such holder's basic Subscription Right at 5c per share. Pursuant to the terms and conditions of the Purchase Agreement, if any Subscription Rights remain unexercised upon the expiration of the Rights Offering after accounting for all Over-Subscription Rights exercised, the standby purchasers will collectively purchase, at the Subscription Price, up to $45M in shares of Common Stock not subscribed for by the company's stockholders. Upon closing of the Rights Offering and in addition to the Backstop Commitment, investors led by Immersion, have agreed through the Private Investment to purchase an aggregate of $50M in shares of the company's Common Stock, at the Subscription Price, in a private placement exempt from the registration requirements under the Securities Act of 1933, as amended. The company intends to use approximately $20M of the proceeds from the Rights Offering and Private Investment to fund transaction-related costs. The company maintains the strong support of its Second Lien Lenders, who will convert all outstanding principal and any accrued and unpaid interest, totaling approximately $34M under the Term Credit Agreement into a number of new shares of Common Stock equal to the quotient of the Debt Amount divided by the Subscription Price. In conjunction with the close of the Rights Offering and Private Investment, BNED has received commitments to refinance its existing ABL Facility pursuant to an agreement with its first lien holders. The new $325M ABL Facility will mature in June 2028 and will eliminate or modify the existing debt covenants to provide greater financial and operating flexibility. The ABL Facility will initially have an applicable margin with respect to the interest rate of 3.50% per annum, in the case of interest accruing based on a Secured Overnight Financing Rate, and 2.5%, in the case of interest accruing based on an alternative base rate. Following the one-year anniversary, the applicable margin shall be reduced one time by 25 basis points per annum if certain financial metrics are met. On April 16, 2024, BNED also entered into an amendment to its credit agreement to amend certain financial covenants to provide additional financial flexibility ahead of the transactions expected closing date in June.

09:30 EDT Johnson & Johnson says no change to M&A strategy - Says has financial flexibility to consider multiple types of transactions.

09:26 EDT Sunrise announces Guizhou Province Governor Li Bingjun's visit to factory - Sunrise New Energy announced that Guizhou Province Governor Li Bingjun, accompanied by a delegation of government officials, conducted an official visit to the Sunrise's plant on April 11, symbolizing the Company's pivotal role within the industry. During the visit, Mr. Haiping Hu, Chairman of Sunrise, presented an overview of the Company's production, technological advancements, energy consumption, and environmental protection efforts. Emphasizing innovation-driven strategies, Mr. Hu highlighted the Company's commitment to reducing costs, enhancing competitiveness, and strengthening meticulous management practices. Governor Li praised Sunrise and its representation of Guizhou's new energy power battery and materials industry. He stressed the importance of optimizing government industrial fund operations to support key industries and enterprises. Furthermore, he emphasized the need to promote coordination among upstream and downstream sectors of the industrial chain to leverage cluster effects effectively. Under the leadership of founder Mr. Haiping Hu, a pioneer in China's lithium battery materials industry, Sunrise has repeatedly set industry records. The Company's elite teams have consistently pursued innovation with 61 patent applications filed domestically and internationally, among which 27 patents have been granted. Sunrise has successfully developed various new anode materials in areas such as artificial graphite, natural graphite, composite graphite, soft carbon, hard carbon, and silicon carbon. Leveraging advanced equipment, the Company continues to develop new materials, processes, and technologies with independent intellectual property rights.

09:23 EDT Scientific Industries, Inc appoints Michael Blechman to board of directors - Scientific Industries announced the appointment of Michael Blechman to the Board of Directors of SI effective April 12, 2024. Mr. Blechman filled a Board vacancy and replaces Mr. Marcus Frampton, who recently resigned, as a Class B director. As CEO of Automated Control Concepts, he led the organization through 20 years of profitable operations and positive shareholder returns, culminating in a successful transaction with a private equity investor.

09:19 EDT PowerBand Solutions provides update on filing of financial statements - PowerBand Solutions announces that as a result of delays in the completion of its audit, the Company will be unable to meet its filing deadline of April 29, 2024, for filing of its audited annual financial statements for the year ended December 31, 2023 and 2022 and management's discussion and analysis for the year ended December 31, 2023 and 2022. The Company was not able to complete the Annual Filings within the time periods required by National Instrument 51-102 - Continuous Disclosure Obligations, due to the delay in commencing the audit owing to the resignation of its previous auditor and the appointment of its successor auditor, HDCPA Professional Corporation. As a result, the Company requires additional time to complete the Annual Filings. In response to the Annual Filings delay, the Company has applied to the Ontario Securities Commission for a management cease trade order under National Policy 12-203 - Management Cease Trade Orders that will prohibit the management of the Company from trading in the securities of the Company until such time as the Annual Filings are filed. No decision has yet been made by the Ontario Securities Commission on this application. The Ontario Securities Commission may grant the application and issue the MCTO or it may impose an issuer cease trade order if the Annual Filings are not filed in a timely fashion. The Company continues to work to complete its annual financial statements for the year ended December 31, 2023 and expects to file the Annual Filings no later than June 29, 2024, and will issue a news release once they have been filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203. The guidelines, among other things, require the Company to issue bi-weekly default status reports, in the form of news releases, for so long as the Annual Filings have not been filed. Until the Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out policy as per its internal Insider Trading Policy that is consistent with the principles in Section 9 of National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. The Company confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the filing on November 30, 2023 of the Company's interim financial reports for the period ended September 30, 2023. There are no insolvency proceedings involving the Company.

09:16 EDT Myriad Genetics announces new study published in Prenatal Diagnosis - Myriad Genetics announced that Prenatal Diagnosis has published a study demonstrating exceptional positive predictive value for 22q11.2 microdeletion screening using Myriad's prenatal cell-free DNA screen, Prequel, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of PPV for the 22q11.2 microdeletion, with several well below 100%.2-6 The proprietary AMPLIFY technology in Prequel increases the relative amount of fetal-derived cfDNA more than two-fold on average and was previously shown to increase analytical performance of 22q11.2 microdeletion screening. The current study shows the clinical performance achieved by Prequel with AMPLIFY: among 22 patients who screened positive for 22q11.2 microdeletion and had diagnostic testing results available, all 22 were confirmed as positive.

09:14 EDT Beamr Imaging presented a demonstration of real-time video streaming capability - Beamr Imaging announced that it has presented a demonstration of real-time video optimization application at the NAB Show 2024, a premier event for the broadcasting, streaming and media industry in Las Vegas, Nevada. Beamr CEO Sharon Carmel said: "The demonstration of Beamr's perceptual optimization technology accelerated by GPUs has the potential to enable efficient video processing at scale in real-time streaming and over 5G. Such an application is poised to be relevant in various use cases, including edge products and the Internet of Things, as 5G bottlenecks are relieved and the streaming of ultra-high-definition video becomes widely available.".

09:12 EDT AMD expands commercial AI PC portfolio - AMD announced new products that will expand its commercial mobile and desktop AI PC portfolio, delivering exceptional productivity and premium AI and connectivity experiences to business users. The new AMD Ryzen PRO 8040 Series are the most advanced x86 processors built for business laptops and mobile workstations.2 In addition, AMD also announced the AMD Ryzen PRO 8000 Series desktop processor, the first AI enabled desktop processor for business users3, engineered to deliver cutting-edge performance with low power consumption.

09:11 EDT Saddle West selects CasinoTrac CMS - Table Trac announced a new agreement to replace a competitor's system with the CasinoTrac casino management system, at Saddle West Hotel Casino & RV Resort, in Pahrump, NV. Executive management at Saddle West expressed excitement about working with CasinoTrac, selecting the CMS because it, "seems like a perfect fit their operations. The a la carte features, security offered through the lightweight server footprint, solid warranties, upgrades, and lifetime licensing set CasinoTrac head and shoulders above the competition."

09:10 EDT Matterport partners with Crunch Fitness to offer advanced photography services - Matterport announced it has partnered with Crunch Fitness, one of the largest fitness companies in North America, to use Matterport's leading digital twin and photography services to ensure brand consistency across marketing materials for its U.S. franchise locations. With this agreement, Matterport will offer Crunch clubs access to nationwide photography, digital twins, and aerial drone photography services to produce rich media content that encourages prospective gym-goers to start their fitness journey with Crunch. "We are thrilled to help Crunch create a more consistent experience across promotional materials that encourages members from every community to participate in fitness," said Jay Remley, Chief Revenue Officer, Matterport. "With our expert photography services and the immersive power of Matterport's digital twins, Crunch Fitness is primed to extend its excellence as a leader in the fitness world across all of its marketing assets."

09:09 EDT Kartoon Studios unveils 'Gadget A.I.' - Kartoon Studios announced the development of a new proprietary generative AI toolkit and workflow, "GADGET A.I.," designed to enable the development, production, and post-production of new animated content, as well as revitalize and upgrade the quality and distribution reach of thousands of existing catalog episodes and acquisitions. Andy Heyward, Chairman & CEO of Kartoon Studios and Co-Creator of the iconic franchise "Inspector Gadget," stated, "During the past year, we have dedicated a great deal of time and resources to understand the opportunities with AI as it pertains to our business and have been speaking extensively with leaders in the field. Our commitment to harnessing AI reflects a pivotal shift in our industry's approach to content creation and distribution. By connecting various tools via OpenUSD into 'Gadget A.I.' with NVIDIA Omniverse, we aim to streamline production processes, accelerate quality, and significantly reduce both time to market and expenditures. Todd has done a brilliant job of using technology to turn Kartoon Channel! to profit in record time for a streaming service, and his fluency in digital technology makes him a natural fit to lead this initiative into the future."

09:07 EDT Kandi Technologies completes redomicile merger - Kandi Technologies Group announced that the reincorporation merger to redomicile the Company as a British Virgin Islands company has been completed on April 16, 2024. Pursuant to the Merger, each outstanding share of the common stock of the Company is converted into the right to receive one ordinary share of Kandi Technologies Group, Inc., a British Virgin Islands company. The ordinary shares of Kandi BVI are expected to trade on the NASDAQ Global Select Market under the trading symbol "KNDI", the same symbol under which the common stock of the Company is listed from 9:30 am E.T., April 17, 2024.

09:05 EDT PubMatic partners with GroupM to deliver AI generated cohort - PubMatic (PUBM) announced a partnership with GroupM, WPP's (WPP) media investment group, to deliver cohort-based modeling capabilities for advertisers. This collaboration, a first-of-its-kind in the market, leverages a distributed AI model via Resolve, a Choreograph company, to enable scaled targeting across multiple publishers simultaneously, ensuring privacy-first ad buying at scale. The proprietary technology utilizes impression level data to generate privacy-compliant audience segments. The technology delivers sustainable scalability for both buyers and sellers, with no personal data moved or shared in the buying process. Data is exclusively connected to inventory on the sell-side, creating enhanced auction packages for advertisers through advanced demand-side tools.

09:04 EDT Definitive Healthcare launches Carevoyance sales enablement solution - Definitive Healthcare announced the launch of Carevoyance, an innovative sales enablement solution tailored for medtech organizations. Acquired by Definitive Healthcare in January 2024, Carevoyance tackles frontline sales challenges head-on. It's a powerful sales acceleration engine that enables medical technology sales and marketing teams to streamline time-consuming tasks, including sifting through data to identify target markets, researching potential customers, and automating reports for strategic sales conversations. This translates to faster sales cycles, more targeted outreach, and ultimately, getting life-saving devices to patients more quickly.

09:03 EDT Autonomix announces issuance of U.S. patent on catheter-based technology - Autonomix Medical announced that the U.S. Patent and Trademark Office has issued U.S. patent 10,143,419 entitled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function." The issued patent is directed to technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain. The Company is initially advancing the development of its technology to address pancreatic cancer-related pain. The Company's catheter-based sensing technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body. The Company is initially developing its technology to address pancreatic cancer-related pain. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

08:59 EDT BofA: Losses on office loans front-loaded, should decline in Q2

08:55 EDT BofA sees low single digit percentage loan growth, moderate deposit growth

08:53 EDT Bank of America sees to be Q2 low point for NII, expects 2H24 NII to grow - Sees Q2 NII approaching $14B on FTE basis.

08:48 EDT WiSA Technologies subsidiary executes five-year WiSA E licensing agreement - WiSA Association, a subsidiary of WiSA Technologies announced that it has executed its fourth five-year WiSA E licensing agreement with a fourth major HDTV/PTV brand. The WiSA E license allows the brand to integrate WiSA E software into its products, thereby offering consumers a variety of wireless immersive audio options including full interoperability with any of the WiSA E-enabled speakers offered by the many WiSA Association speaker brands.

08:47 EDT Planet Fitness appoints Colleen Keating as CEO - Planet Fitness has appointed Colleen Keating as the company's CEO, effective June 10. At that time, Craig Benson will resign as Interim CEO but will continue to serve as a member of the Board. Keating has served as CEO of FirstKey Homes since 2020. Prior to joining FirstKey, Keating served in a variety of roles of increasing responsibility at InterContinental Hotels Group, including Chief Operating Officer, Americas, and Starwood Hotels & Resorts Worldwide.

08:45 EDT Iteris awarded $900K contract for multimodal Port of Long Beach study - Iteris announced it has been awarded a $900,000 contract by the Port of Long Beach for an 18-month multimodal transportation study.The project will identify how best to accommodate cargo movement within the Port to enhance safety and efficiency for various transportation modes, including trucks, rail, transit, bicyclists, and pedestrians. It will also coordinate future Port development and infrastructure improvements. Iteris is leading a team of partner firms, including HDR Inc., System Metrics Group, Raju Associates, and Valerie Martinez Associates Communications, Inc., to provide comprehensive services.

08:42 EDT QT Imaging: 2nd blinded screening trial finds technology as effective as DBT - QT Imaging Holdings announces positive data regarding the diagnostic performance of QTI's Breast Acoustic CTTM Scans for mass detection from its second blinded multi-reader multi-case study. The study was published in Academic Radiology, online, in January 2024: A Multireader Multicase MRMC Receiver Operating Characteristic ROC Study Evaluating Noninferiority of Quantitative Transmission QT Ultrasound to Digital Breast Tomosynthesis DBT on Detection and Recall of Breast Lesions - Academic Radiology...Twenty-four breast radiologists participated in a study of 177 selected cases. The study found that QTI's Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis DBT , also known as 3D mammography, in that the area under receiver operating characteristic curve AUC was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05. This means that QTI technology is non-inferior to DBT in the detection of breast lesions as a whole, with high specificity in determining benign cysts and thus decreasing benign recall rates. Statistical analysis was performed by Dr. Yulei Jiang from the Department of Radiology of the University of Chicago..."We are encouraged by the consistent high performance of QTI's technology, especially in women with dense breasts. Along with the previously published results and from comparison of QTI's scans with mammography, these trial results will be valuable for our planned FDA submission for a screening indication in younger women identified with above-average risk for developing breast cancer and who have not yet reached the age for conventional mammography-based screening," said Dr. Bilal Malik, Chief Science Officer. The results of the study comparing QTI's technology performance with mammography were published in Academic Radiology, in December 2020: An Exploratory Multi-reader, Multi-case Study Comparing Transmission Ultrasound to Mammography on Recall Rates and Detection Rates for Breast Cancer Lesions - Academic Radiology

08:41 EDT GRI Bio issued grant from Korean Intellectual Property Office - GRI Bio announced that the Korean Intellectual Property Office has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions." The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT cells in the prevention and treatment of inflammatory conditions of the liver. More specifically, when issued the patent will cover the prevention and treatment of inflammatory and fibrotic conditions through the administration of a Retinoic Acid Receptor agonist that inhibits iNKT cells and the administration of an RAR agonist that inhibits the activity of iNKT cells in a subject. "We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators. Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases. As we continue to advance our development programs forward, we remain steadfast in our commitment to expand our IP globally and position the Company to address the global unmet need amongst patients for much needed treatment options," Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

08:39 EDT Solowin Holdings selected as dealer for Harvest Global's Bitcoin, Ethereum ETF - SOLOWIN HOLDINGS has been selected as one of the three participating dealers for Harvest Global's spot Bitcoin and Ethereum ETF in Hong Kong. Harvest Global was one of the just three ETF providers to receive conditional approval from the Hong Kong Securities and Futures Commission (SFC) this week to launch spot Bitcoin and Ethereum ETFs. The conditional approval, coming just three months after the U.S. introduced similar ETFs which attracted around $12 billion in investments, marks a significant regulatory advancement for Hong Kong's aspirations to be a global virtual asset hub. The virtual asset spot ETFs in Hong Kong will also introduce an in-kind subscription mechanism that allows investors to buy into the ETF using Bitcoin or Ethereum directly. This is expected to act as a transformative vehicle for channelling significant investment into the virtual asset space.

08:38 EDT Telomir Pharmaceuticals unveils pre-clinical data on age-reversal drug - Telomir Pharmaceuticals recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024. Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging. As part of its commitment to transparency and openness in sharing its research data, during the event, Drs. Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres. The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.

08:38 EDT Ducommun rejects non-binding indication of interest from Albion River - Ducommun responded to an unsolicited, non-binding indication of interest dated April 1, 2024 from Albion River to acquire all outstanding shares of Ducommun for $60.00 per share in cash. The company said, "The Board of Directors has unanimously determined it is not in the best interests of the Company and Ducommun shareholders to pursue further discussions regarding the proposal. Consistent with its fiduciary duties and in consultation with its legal and financial advisors, our Board of Directors carefully reviewed and considered the offered pricing and the underlying proposed actions. Following that review, our Board of Directors concluded that the Company's previously disclosed Vision 2027 Strategy reflects a substantially better long-term value creation opportunity for Ducommun's shareholders. Over the past seven years, our Board and Management team have effectively transformed the Company's business with strategic acquisitions of engineered product businesses with high aftermarket mix, implementation of a value-based pricing strategy, significant facility consolidation, improved operations and customer metrics, a leaner management structure and many other cost reduction actions. Despite the impact of the COVID-19 pandemic and the 737MAX on our markets, Ducommun's revenue has grown from $551M in 2016 to a new all-time revenue record of $757M in 2023. Also, Ducommun's EBITDA margins have expanded from 10% in 2016 to 13% in 2023. As a result, the Company's shareholders benefitted from an increase in market capitalization from approximately $286M at the end of 2016 to approximately $760M at the end of 2023. In addition, the Company managed through the COVID-19 pandemic and 737MAX with limited impact on its Adjusted EBITDA despite significant deterioration in the commercial aerospace industry. This was accomplished by growing its military and space business from $278M in 2018 to $421M in 2022 and through proactive cost management. Since December 2022, Ducommun management has been executing its Vision 2027 Strategy by consolidating its facility footprint, continuing its targeted acquisition program, increasing the revenue proportion of engineered product and aftermarket content, executing our offloading strategy with defense primes in high growth segments of the defense budget, and by expanding content on key commercial aerospace platforms. These strategic initiatives already have positioned Ducommun to benefit from the continuing recovery in aircraft production rates over the next several years. Ducommun's market capitalization has increased to approximately $760M at the end of 2023 from approximately $605M at the end of 2022, a 25.6% increase in a single year. Our Board of Directors and management team expect that, as previously disclosed in our Vision 2027 Strategy, by 2027 Ducommun will achieve $950M to $1,000M in net revenues, with approximately 18% adjusted EBITDA margins. This would represent a gain of approximately 470 basis points since 2022 and approximately 13% adjusted operating income margins. Our Board of Directors therefore believes that Albion River's offered price and generic proposed actions significantly undervalues Ducommun and could distract our team from our Vision 2027 Strategy. Therefore, our board has reaffirmed that Ducommun is not for sale. We remain committed to our proven strategy to substantially grow the value of Ducommun. We value the views of our shareholders, and we are happy to consider any useful ideas to increase the long-term value of Ducommun. Our Board of Directors and management will continue to listen to all Ducommun shareholders and act in their collective best interests."

08:37 EDT Nano Dimension appoints Ben-Eliahu to board of directors - Nano Dimension announced that Major General Eitan Ben-Eliahu is joining its Board of Directors. Major General Ben-Eliahu is currently the President of International Flight Academy, a board member of Gadfin Ltd. and RoutePerfect Ltd., and Chairman of the College Academic Center of Law & Business.

08:35 EDT SP Plus launches its Bags branded technology at New Brightline - SP+ Corporation announced a partnership with its subsidiary Bags and Brightline high-speed rail service. Bags provides luggage handling services along with technology to print luggage tags and tracking of baggage throughout the journey between Orlando International Airport and the downtown Miami station. "SP+ collaborated with Brightline to streamline their customer experience," said Billy Arden, SVP, Bags. "Considering SP+'s creative and innovative technology solutions in baggage handling and labor, along with our proven expertise for efficiently printing bag tags; we worked collaboratively with Brightline to simplify and enhance the customer experience."

08:33 EDT Palisade Bio demonstrates bioactivation of PALI-2108 - Palisade Bio announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by UC. These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC. The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period. The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time. The study was conducted in collaboration with Altasciences based in Montreal, QC.

08:32 EDT Rigetti Computing, Oxford Instruments complete U.K. project - Rigetti UK Limited, a wholly owned subsidiary of Rigetti Computing, and Oxford Instruments NanoScience, a leading provider of cryogenic systems, announce that their three-year project to build and operate one of the first quantum computers in the UK has been successfully completed. The consortium also included the Quantum Software Lab at the University of Edinburgh, Phasecraft, and Standard Chartered Bank. The goals of the Rigetti-led GBP 10 million consortium were to accelerate the commercialization of quantum computing in the UK through the delivery of a quantum computer in the UK, by advancing practical applications in machine learning, materials simulation, and finance, and furthering the development of the UK's quantum computing talent, infrastructure, and national supply chain. The consortium was backed by funding from the UK government's Quantum Technologies Challenge, led by UK Research & Innovation. Dr. Subodh Kulkarni, Rigetti CEO, said, "Completing this project, with the end result being a useful 32-qubit quantum computer, is an exceptional achievement for all of the project partners. It takes a world-class team to build and deploy a quantum computer. The UK has become a world leader in quantum computing technologies, and we are excited to continue to contribute to its quantum computing capabilities. Additionally, Rigetti plans to leverage this experience to continue to develop our UK quantum computing leadership as we embark on deploying a 24-qubit Ankaa-class quantum computer at the NQCC's Harwell campus."

08:19 EDT Peraso says Panasonic uses X710 chipset for 60GHz WLAN solution - Peraso announced that Panasonic System Networks R&D Lab has adopted Peraso's X710 chipset for its new 60GHz WLAN solution. Incorporating Peraso's phased array antenna technology, PSNRD's newly introduced 60GHz WLAN solution achieves wireless high-speed, low-latency communication equivalent to wired LAN over distances of hundreds of meters. The new solution is easy to install and operate thanks to its unlicensed, interference-free use of the 60 GHz band and narrow beam directional antenna control.

08:17 EDT Alpha Modus entered IP license agreement with Xalles Holdings - Alpha Modus announced it has entered into an intellectual property license agreement with Xalles Holdings and its wholly owned subsidiary CashXAI. CashX, through its proprietary self-service kiosks and mobile application, allows the unbanked and underbanked communities access to financial services, including digital currency. The license agreement licenses to Xalles and its subsidiary, CashX, the exclusive right to use all of Alpha Modus' patented intellectual property in connection with CashX's promotional, advertising, and operational functions, including co-development arrangements with Alpha Modus, within the Exclusive Industry. The "Exclusive Industry" means the industry relating to self-service kiosks located in retail food, drug and convenience stores for the purpose of serving Unbanked and Underbanked consumers, by offering banking, phone and insurance solutions to the consumer. Effective as of October 13, 2023, Alpha Modus entered into a business combination agreement with Insight Acquisition Corp, pursuant to which Alpha Modus would be acquired by Insight

08:16 EDT Ocean Power announces teaming agreement with defense contractor - Ocean Power Technologies announced it has signed a teaming agreement with a major international defense contractor to provide its Merrows suite of solutions with a focus on certain geographic regions. This alliance is set to advance maritime domain awareness through OPT's innovative Maritime Domain Awareness Solution, MDAS. Under the terms of the agreement, the defense contractor will have exclusive rights to provide OPT's MDAS solution within certain international geographic regions. Leveraging OPT's cutting-edge technology alongside the international contractor's extensive expertise in defense, homeland security, and commercial programs, the collaboration aims to strengthen the contractor's capabilities in maritime security and surveillance. Philipp Stratmann, CEO and President of Ocean Power Technologies, expressed enthusiasm about the alliance, stating, "We are thrilled to join forces with a major international defense contractor to provide our Merrows suite of solutions to certain international regions. This collaboration underscores our commitment to enhancing maritime security globally, and we are confident that together, we are positioned to achieve remarkable advancements in this field."

08:14 EDT Genetic clinicians' adoption growing, sales up 5-fold year-over-year - Genetic Technologies shares the company's latest milestones along with our clinical adoption of the Company's groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets. Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia. Commercial tests received for the 6 months ending March 31, 2024 increased 543%, when compared with the same period last year, demonstrating the company is well on a pathway to profitability.

08:13 EDT Teva announces final results from the HD cohort study for Austedo at AAN - Teva Pharmaceuticals announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology AAN Annual Meeting. "90% of HD patients experience chorea,3,4 so it's important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience," said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. "We remain committed to exploring ways to evolve the AUSTEDO treatment experience to meet the needs of the HD community, and these latest real-world data reinforce the role of the 4-week Titration Kit for AUSTEDO in empowering patients with HD chorea to find their optimal dose, adhere consistently to their treatment plan, and achieve effective outcomes."

08:12 EDT Daxor announces two new studies on BVA - Daxor Corporation announces two new studies validating the clinical benefits of blood volume analysis, BVA, as a more precise measurement of congestion in ambulatory heart failure patients. Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA. The study titled, 'Impact of Systemic and Pulmonary Afterload on the Pressure-Volume Relationship in Heart Failure Using Direct Blood Volume Measurement,' was presented at the American College of Cardiology Scientific Sessions 2024. A research letter published in the American Heart Journal, titled, 'Prognostic Implications of Volume Status Assessed by Blood Volume Analysis in Ambulatory Heart Failure,' was authored by leading heart failure experts from Duke University Medical Center, Baptist Memorial Hospital and Banner University Medical Center.

08:09 EDT Banzai welcomes over 580 new customers in Q1 - Banzai International announced exceptional customer growth in Q1 2024. Banzai added over 580 customers in Q1 2024. Of this, 400 were net new customers and 180 were reactivating customers since January 1, 2024, highlighting the effectiveness of Demio, Banzai's webinar platform, and Reach, the company's event marketing solution. Banzai's new customer acquisition represents a quarterly increase of 46% compared to the 397 net new and reactivating customers Banzai added in Q4 2023. The majority of this increase was driven by growth in the Demio business unit, with additional momentum from sales and marketing execution in the Reach business unit. "Our team's first-quarter achievements underscore Banzai's commitment to delivering exceptional value to our customers, as well as expanding the makeup of our customer base across industries and further up-market," said Joe Davy, Chairman and CEO of Banzai. "We're thrilled by the momentum we've achieved so far this year, which positions us for sustained growth throughout 2024."

08:08 EDT Monopar Therapeutics announces filing of patent protecting MNPR-101 - Monopar Therapeutics announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled "Antibody Radioisotope Constructs" that was filed with the United States Patent and Trademark Office outlines the MNPR-101-Zr construct, including variations on the radioisotopes, linkers, and antibody which could enhance the clinical profile of the construct, including properties such as its stability and biodistribution. It also covers the formulations and uses of MNPR-101-Zr, a zirconium-89 imaging radioisotope labeled version of MNPR-101, Monopar's proprietary first-in-class humanized monoclonal antibody that is highly-selective against the urokinase plasminogen activator receptor. "Filing of this provisional patent application is aimed at further protecting our novel MNPR-101 radiopharmaceutical program," said Chandler Robinson, MD, Monopar's Chief Executive Officer. "This patent filing along with our earlier patent filings helps to create a broad portfolio of intellectual property around this program and potential future programs."

08:07 EDT Intermex announces strategic partnership with Felix Pago - Intermex has announced its strategic partnership with Felix Pago. The Felix Pago partnership with Intermex, creates a user-friendly chat-based platform, aimed at facilitating money transfers for Latin American families in the US to their loved ones back home. This alignment between Felix Pago and Intermex marks a new era in money transfers, focusing on ease, speed and accessibility. Marcelo Theodoro, Chief Product, Marketing & Digital Officer at Intermex, stated, "We're all about making things easier for our customers. Teaming up with Felix Pago is exciting for us. We are bringing together the best of both worlds - our proven remittance platform and their easy-to-use system." He added, "We're looking forward to bringing more options to people and making a big difference in how families support each other across Latin America. This partnership is a big step in making sure everyone can send money easily, no matter where they are."

08:07 EDT Browning West cautions Gildan shareholders on 'risky path forward' - Browning West , which is a long-term shareholder of Gildan Activewear and beneficially owns approximately 5.0% of the Company's outstanding shares, today issued the following statement regarding the Company's April 15th investor update. As a reminder, Browning West is seeking to elect eight highly qualified and independent director candidates to Gildan's Board of Directors at the Annual Meeting of Shareholders on May 28. Browning West's director candidates possess strong track records of value creation, expertise in successful succession planning, relevant industry and governance experience, as well as proven management and board service pedigrees in Canada and the U.S. "Browning West believes that Vince Tyra's 'new plan' raises troubling questions about the current Board's stewardship of the Company and confirms our fears that Mr. Tyra may lead Gildan down a similar destructive path as the ones he did at the helm of Fruit of the Loom Inc. and Broder Brothers Co

08:06 EDT NuCana announces completion of ADS ratio change - NuCana announced that the Company's previously disclosed plans to change the ratio of its American Depositary Shares to its ordinary shares from one ADS, representing one ordinary share, to one ADS representing twenty-five ordinary shares has been made effective. The ADS Ratio Change became effective on April 16, 2024. For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty-five reverse ADS split and will have no impact on an ADS holder's proportional equity interest in the Company. The change in the ADS Ratio is intended to further support the liquidity in the Company's ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement. The exchange of one new ADS for twenty-five then-held ADSs occurred automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by Citibank, N.A., the depositary bank. Registered holders of the Company's ADSs held in certificated form were required on a mandatory basis to surrender their certificated ADSs to the Depositary for cancellation and received one new ADS in exchange for every twenty-five existing ADSs then-held. Holders of uncertificated ADSs in the Direct Registration System and the Depository Trust Company had their ADSs cancelled and automatically exchanged, receiving one new ADS for every twenty-five existing ADS then-held. The Company's ADSs continue to be traded on the Nasdaq Capital Market under the ticker symbol "NCNA". The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company's equity, except to the extent that the ratio change would have resulted in a shareholder owning fractional ADSs. No fractional new ADSs were issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the Depositary. As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company's ADSs.

08:04 EDT Compass Therapeutics announces first patient dosed in Phase 1 study of CTX-8371 - Compass Therapeutics announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors. "Dosing the first patient in the CTX-8371 Phase 1 represents the advancement of our third program into the clinic, which is an important milestone for the company," said Vered Bisker-Leib, PhD, Chief Executive Officer. "We recently published preclinical data in the peer-reviewed journal, OncoImmunology, supporting the novel mechanism of action of CTX-8371: proteolytic cleavage and subsequent loss of cell surface PD-1. We believe this mechanism drives the enhanced anti-tumor activity of CTX-8371 in preclinical models when compared to approved anti-PD-1 and PD-L1 therapies and warrants its evaluation in patients."

08:03 EDT Greif prepares for opening of new facility in Dallas, Texas - Greif is finalizing construction on their new bulk corrugated manufacturing facility in Dallas, Texas. Scheduled to open later this spring, the new facility will significantly expand Greif's capacity in the bulk corrugated business and create opportunities in the South and Southwest regions of the United States, as well as Mexico. "We are delighted to establish this new facility in Dallas, Texas," said Chris Zimmerman, Vice President - Containerboard & Corrugated Sales. "We have formed an excellent team who have worked extremely hard to get this state-of-the-art facility up and running. Equipped with highly automated machinery, this facility will enable us to respond swiftly to customer demands while maintaining superior lead times and product quality."

08:03 EDT Incannex provides quarterly update - Clinical stage pharmaceutical development company, Incannex Healthcare provides quarterly activities update and for the quarter ended 31 March 2024. Incannex is undertaking various U.S. Food and Drug Administration research and development programs for cannabinoid pharmaceutical products and psychedelic medicine therapies. The nearest-to-market projects in the Company's therapeutic pipeline are: IHL-42X drug candidate for Obstructive Sleep Apnea - Phase 2/3 studies underway. IHL-675A drug candidate for Rheumatoid Arthritis - Phase 2b studies also underway. Psi-GAD psilocybin treatment protocol for generalised anxiety disorder: Phase 2b studies commencing following successful Phase 2 proof of concept studies in 73 patients. Clarion Clinics - opens first clinic for the provision of psychedelic-assisted psychotherapies in regulatory permissible locations.

07:53 EDT Enlivex announces DKMA authorization for Phase I/II trial of allocetra - Enlivex Therapeutics announced that the Danish Medicines Agency authorized the expansion into Denmark of the Company's multi-country, randomized, controlled Phase I/II trial evaluating Allocetra in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health in January. The Phase I/II multi-center trial is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the target knee in order to identify the dose and injection regimen for the second, randomized stage. The second stage is a double-blind, randomized, placebo-controlled stage, which the Company expects to initiate following the completion of the safety run-in stage and confirmation by the independent Data and Safety Monitoring Board. In addition to evaluating safety, the blinded randomized stage is statistically-powered to assess the efficacy of Allocetra injections into the knee. The Company expects that the primary measurements will evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months after treatment.

07:51 EDT StoneCo adopts new internal accounting policy - The Company announces that, beginning in the first quarter of 2024, it will adopt a new internal accounting policy for the recognition of membership fee revenues. Membership fee revenue is generated from a non-refundable set up fee paid upfront by a merchant client upon the signing of its service agreement contract for some of our offerings. Previously, the Company recognized the entire membership fee at the time it was paid. Under the new policy, the recognition of these revenues will be deferred through the expected lifetime of the merchant client. For fiscal year 2023, membership fee revenue accounted for R$316 million in net revenue from transaction revenues. This change is expected to: Have no impact on our 2024 Guidance given the strong continued performance of the business. Have no impact on the Company's cash position or its ongoing cash flow generation. Reduce transaction revenues by approximately R$60-70 million in 1Q24 and R$160-200 million in FY2024 and increase deferred revenue liabilities by the same amounts in 1Q24 and FY2024.

07:43 EDT RF Code, Schneider Electric team on data center management - RF Code announced a worldwide strategic partnership with Schneider Electric..Through the partnership, RF Code's intelligent software-enabled wire-free hardware is integrated with Schneider Electric's data center infrastructure management solution, EcoStruxure IT. The outcome of this integration eliminates costly error-prone and manual processes and ensures 99 percent accurate asset tracking and chain of custody data in real-time. "Building upon EcoStruxure IT's existing partner ecosystem, this integration provides real-time visibility into asset data for both IT and facilities managers, enabling a key next step in automated service deliveries and data center service optimization," said Kevin Brown, Senior Vice President, EcoStruxure Solutions, Secure Power Division, Schneider Electric. "We're excited about the integration of our EcoStruxure IT DCIM solution with RF Code and continue on the path towards holistic management of IT and facilities."

07:35 EDT ParaZero to enter counter unmanned aircraft system market - ParaZero Technologies announced its intention to enter the counter unmanned aircraft system market, by developing dedicated solutions based on its advanced technology, as announced on February 27, 2024. Small, lethal drones are being utilized around the world with tremendous effectiveness and are reshaping the balance between humans and technology in war, raising demand for C-UAS countermeasures. Counter-drone technology encompasses a wide range of solutions that allow users to detect, classify, and mitigate drones and unmanned aerial vehicles. This includes everything from camera systems and specialist drone detection radars to net guns and cyber takeover systems. Following an extensive due diligence process, the Company analyzed the expanding market of C-UAS technologies and believes that specific elements within its unique proprietary technology portfolio, as well as the Company's ability to rapidly design, develop, and manufacture advanced UAS technologies, strongly positions the Company to offer a competitive edge in defending against threats and attacks from small UAS platforms. The decision to explore these avenues also correlates to global inquiries the Company has received from various entities to explore entering this market. Presently, the Company believes that there is increased market demand for C-UAS technology for a myriad of site applications yet limited mitigation options.

07:34 EDT Lilium starts production of high-performance battery packs for Lilium Jet - Lilium announced that it has started production of the advanced, aviation grade battery packs that will power the Lilium Jet on its first piloted flight, targeted for end of 2024. This latest milestone represents a landmark in the development of the Lilium Jet and follows extensive testing of battery pack subcomponents from individual cell to stack level with a focus on performance, safety and regulatory conformity. Yves Yemsi, COO of Lilium said: "The start of production of the battery packs is a proud moment for Lilium. Battery technology is central to the goal of delivering sustainable regional air mobility, including overcoming the challenges of developing and industrializing a battery pack that will meet the stringent safety standards of aircraft certification. With the start of production of the Lilium Jet's unique high-performance aircraft battery packs, Lilium has laid a further cornerstone towards realizing the vision of electric aviation."

07:33 EDT Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates - Eloxx Pharmaceuticals provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation for ELX-02. ELX-02: Regulatory and Clinical Updates for Alport Syndrome Nonsense Mutation Program: ELX-02 Granted ODD from U.S. FDA: In April, the FDA Office of Orphan Products Development granted ODD for ELX-02 for the treatment of Alport Syndrome. Requested a Pre-Investigational New Drug meeting with U.S. FDA: The request for a pre-IND meeting formally initiates communications with the FDA regarding development of ELX-02 for the treatment of NMAS. Presented Clinical Data Updates at Alport Workshop Meeting in March: Prof. Daniel Gale presented updated results from the Proof-of Concept Study in 3 NMAS patients treated with ELX-02. Meaningful reduction in Podocyte Foot Process Effacement after treatment measured as an average 60% increase in Filtration Slit Density in post treatment kidney biopsies in all 3 patients. Results confirm the expression of functional collagen 4 protein in-line with the mechanism of protein induction of ELX-02. ZKN-013: Update on Global Licensing Partnership with Almirall: In March 2024, Eloxx announced an exclusive license agreement with Almirall to develop and commercialize ZKN-013 in orphan indications including RDEB and FAP with nonsense mutations. Received $3 million in upfront payment. Additional payments of ELX-02 of up to $470 million and tiered royalties on global sales: Eloxx shall be eligible for additional payments throughout the potential development phases, including regulatory and sales milestones of up to $470 million as well as tiered royalties on any potential global sales. Initiated Phase 1 Single Ascending Dose study: Initiated Phase 1 SAD study in Australia with initial results expected in 2nd half of 2024

07:27 EDT Trump Media's Truth Social to launch streaming platform - Trump Media & Technology Group's Truth Social announced that after six months of testing on its Web and iOS platforms, the Company has finished the research and development phase of its new live TV streaming platform and will begin scaling up its own content delivery network. TMTG plans to roll out its streaming content in three phases: Phase 1: Introduce Truth Social's CDN for streaming live TV to the Truth Social app for Android, iOS, and Web. Phase 2: Release stand-alone Truth Social over-the-top streaming apps for phones, tablets, and other devices. Phase 3: Release Truth Social streaming apps for home TV. The streaming content is expected to focus on live TV including news networks, religious channels, family-friendly content including films and documentaries; and other content that has been cancelled, is at risk of cancellation, or is being suppressed on other platforms and services.

07:24 EDT Biotricity launches cardiac monitoring pilot program with hospital network - Biotricity launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. The pilot program will demonstrate the value of Biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network. As part of the pilot program, Biotricity will collaborate closely with the hospital network to gather data, refine patient interaction protocols, and enhance the overall utility of its technology suite. This initiative is expected to provide valuable insights that will further drive the evolution of Biotricity's solutions suite to deliver award-winning, best-in-class predictive monitoring tools that pave the way for groundbreaking disease profiling, enhanced patient management, and a transformative approach to disease prevention.

07:22 EDT Signal Gold initiates further drilling at western extension of Goldboro - Signal Gold will initiate further exploration drilling on the western extension of the Goldboro Deposit at the Company's Goldboro Project in Nova Scotia. The drill program, which will be comprised of up to 5,000 metres of diamond drilling, will follow-up on the Company's discovery in 2023 of near-surface, high-grade gold mineralization immediately west of the Goldboro Deposit, all located within the same anticline which hosts the Goldboro Deposit. Initial geological modelling of the gold mineralization identified in 2023 indicates the potential to delineate additional open-pit Mineral Resources, and the potential for further gold discoveries. "We are excited to initiate further drilling at the western extension of the Goldboro Deposit and follow-up on our 2023 discovery of continued gold mineralization to the west, which brings the total strike length of known gold mineralization to 3.4 kilometres at Goldboro. Preliminary geological modelling of the drill results from the western extension demonstrates the potential to both develop an open-pit mineral resource and expand the known gold mineralization. This drill program will allow us to further advance and refine the geological model and the open-pit mineral resource potential. Concurrently, we also see further potential for discovery regionally following recent data compilation and ongoing airborne geophysical surveys over our significantly expanded land package and will be providing further guidance on regional exploration targets in the near future. The initiation of drilling of the western extension combined with ongoing regional exploration continues to demonstrate the scale potential of the Goldboro Gold District." said Kevin Bullock, President and CEO, Signal Gold Inc.

07:18 EDT Arch Biopartners announces St. Michael's Hospital joined Phase II for LSALT - Arch Biopartners announced that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury. LSALT peptide is the Company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. "Our research team is excited to be participating in this trial. Organ injury and repair is a Unity Health Toronto Research Pillar, and we are committed to investigating key mechanisms underlying tissue injury and healing, and to developing therapies to reduce injury and enhance regeneration," said Dr. David Mazer, translational researcher, anesthesiologist, and intensivist at St. Michael's Hospital.

07:16 EDT SAB Biotherapeutics provides SAB-142 trial update - SAB Biotherapeutics announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far. In October 2023, SAB received approval by the Australian Human Research Ethics Committee to commence the Phase 1 clinical trial investigating safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of SAB-142. The primary objective of the trial is two-fold: to generate data on differentiated safety and immunogenicity of this human immunoglobulin, and to establish a Proof of Biological Activity for SAB-142. Phase 1 of SAB-142 is a randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with T1D. SAB-142 is a first-in-class human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.

07:15 EDT Treace Medical announces first annual National Bunion Day - Treace Medical Concepts announced the first-ever National Bunion Day in the United States. National Bunion Day is an opportunity to help more people learn about the identification and treatment of this common bone deformity in the foot, which often includes debilitating pain for millions of adults in the U.S.

07:14 EDT Clearside Biomedical appoints Gibney to board of directors - Clearside Biomedical announced that Anthony Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. Most recently, Gibney served as the Executive Vice President, Chief Business & Strategy officer of Iveric Bio.

07:13 EDT Ocular Therapeutix announces appointments of CMO, CDO - Ocular Therapeutix announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer, CMO; Peter Kaiser, MD as Chief Development Officer, CDO; Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant. Dr. Waheed's appointment will be effective as of May 20, 2024. Jeffrey Heier, MD, will continue in his role as Chief Scientific Officer.

07:12 EDT AstraZeneca: Imfinzi + chemo doubled OS at three years for patients with BTC - Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI or durvalumab, in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival OS benefit at three years for patients with advanced biliary tract cancer, BTC. These results from TOPAZ-1, which are the longest survival follow-up ever reported for a global, randomized Phase III trial in this setting, will be presented on April 18 at the 2024 Cholangiocarcinoma Foundation Conference in Salt Lake City, Utah. .. Stacie Lindsey, CEO, Cholangiocarcinoma Foundation said: "AstraZeneca's longer survival data in advanced biliary tract cancer represents a meaningful milestone in that we are seeing three-year survival data for the first time for these patients. The data spurs hope that research will continue to improve outcomes for patients living with these challenging and rare cancers."

07:10 EDT Multi Ways Holdings partners with PNGFA to promote economic growth - Multi Ways Holdings announces a strategic partnership with the Papua New Guinea Forest Authority, PNGFA, by establishing a dedicated office within its Singapore headquarters. This initiative facilitates outreach to local and international investors, encouraging investment into Papua New Guinea to foster economic growth and development. James Lim, Chairman and CEO of Multi Ways, commented, "We are honored to host the Papua New Guinea Forest Authority within our Singapore headquarters. This collaboration not only underlines our commitment to sustainable development but also opens up new avenues for economic growth in PNG. We believe that by connecting PNG with potential investors, we can contribute to a prosperous future that benefits all stakeholders involved."

07:09 EDT Foghorn Therapeutics appoints Humer as Chief Financial Officer - Foghorn Therapeutics (FHTX) announced that Kristian Humer will join the company as Chief Financial Officer on April 16, 2024 Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry. Prior to joining Foghorn, Humer most recently held executive roles at Viridian Therapeutics (VRDN), where he successfully led financial strategy and business development as the Chief Financial Officer and Chief Business Officer.

07:08 EDT Intra-Cellular announces Phase 3 results from Study 501 - Intra-Cellular Therapies announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder. Topline results from our second Phase 3 study, Study 502, are anticipated late in the second quarter of this year. "The positive Phase 3 results in MDD represent a significant step towards our goal of further establishing CAPLYTA as a first-choice treatment across mood disorders," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "We believe that these robust efficacy results coupled with its favorable safety and tolerability profile and convenient dosing make CAPLYTA a compelling option as an adjunctive treatment for MDD, if approved. At ITCI, we are committed to bringing improved treatment options to patients with major neuropsychiatric conditions through our efforts to expand CAPLYTA's label and advance our pipeline." Lumateperone 42 mg given once daily as adjunctive therapy to antidepressants met the primary endpoint in Study 501 by demonstrating a statistically significant and clinically meaningful reduction in the MADRS total score compared to placebo at Week 6. In the modified intent-to-treat study population, the least squares mean reduction from baseline for lumateperone 42 mg was 14.7 points, versus 9.8 points for placebo. Lumateperone 42 mg also met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the CGI-S score compared to placebo at Week 6. Statistically significant efficacy was seen at the earliest time point tested and maintained throughout the study in both the primary and the key secondary endpoints.

07:06 EDT Arko Corp. subsidiary to open new Handy Mart in North Carolina - ARKO announced that its subsidiary GPM broke ground with a New To Industry Handy Mart branded location at 2934 Highway 24, Newport, North Carolina that is scheduled to open later this year. This location is the second announced New To Industry location in process that the Company has announced in the last 30 days. "We have been very happy with the performance of our Handy Mart stores, which we acquired in November of 2021, and our ability to improve performance at those stores," said Arie Kotler, President & CEO of ARKO. "Building upon the strong community ties of the Handy Mart brand in North Carolina, we are very excited to begin construction on our first New To Industry location under the Handy Mart banner since our acquisition, which will showcase many of our new initiatives and offerings in a beautiful and inviting store design. The addition of this new store is just another destination where customers that enroll in our loyalty program, fas REWARDS, can take advantage of daily, significant savings."

07:06 EDT Cyngn receives notice of allowance for 20th U.S. patent - Cyngn announced the notice of allowance for a new patent, 17/812,072, for the company's autonomous vehicle solutions. This patent covers the generation of a compensated environmental model by applying methods to address challenges that arise from using sensors that are in motion while collecting data and the inherent processing delay that exists between sensing and generating an environmental model.

07:06 EDT Beneficient announces 1-for-80 reverse stock split - Beneficient announced a 1-for-80 reverse stock split of its Class A common stock, par value $0.001 per share, and its Class B common stock, par value $0.001 per share. The Reverse Stock Split was previously approved by Beneficient's stockholders on March 21, 2024.

07:04 EDT Solaris Resources to commence trading on NYSE American - Solaris Resources received approval to list its common shares on the NYSE American with trading expected to commence on Friday, April 19, 2024 under the symbol "SLSR". The Company will remain listed on the Toronto Stock Exchange under the symbol "SLS". Concurrent with the start of trading on the NYSE American, the Company's common shares will cease trading on the OTCQB Venture Market. Shareholders are not required to take any action. The Company recommends that investors who have bought shares on the OTCQB Venture market monitor their accounts to ensure that their holdings correctly reflect the new ticker symbol.

07:02 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 50,500 shares of EyePoint Pharmaceuticals common stock to seven new employees. The stock options were granted on April 15, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $21.28 per share, the closing price of EyePoint Pharmaceuticals' common stock on April 15, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

06:49 EDT Telus International and Appian expand partnership for AaaS platform - Telus International (TIXT) is expanding its strategic partnership with Appian (APPN) to provide clients with an end-to-end value chain through an intelligent automation as a service - AaaS - platform. Through the Appian partnership, Telus International has established a unified, AI-powered IT ecosystem. This ecosystem combines technologies, such as AI, machine learning, and robotic process automation, and incorporates a data fabric architecture that integrates next-gen, enterprise-wide data management and delivery across endpoints on-premises and in multiple cloud environments. Appian's low-code process automation platform enables individuals to build applications with a visual interface. Using Telus International's enhanced Automation as a Service platform that incorporates Appian's low-code application development capabilities, Telus' employees were able to develop network build tools with a variety of functionalities, such as network design, configuration, deployment, and optimization, much faster than with traditional methods. This has improved business workflow automation in the company's critical business activities for Telus networks, resulting in savings of C$5M in 2023.

06:43 EDT Johnson & Johnson sees 'slightly stronger' sales in Innovative Medicine in 1H24 - Innovative Medicine: Expects slightly stronger sales growth in the first half of the year compared to the second. Sees continued uptake from recently launched products. Anticipates entry of Stelara biosimilars in Europe towards the middle of the year. MedTech: Operational sales growth expected to be relatively consistent throughout the year. Expects 2024 procedure volumes to remain above pre-COVID levels. Sees modest impact from Russia sanctions in first half of the year. Sees VBP pricing for Surgical IOLs and Sports in 2024; lapping of 2023 VBP impacts throughout the year. P&L: EPS growth will benefit from 191M share reduction in the first half of the year; partial benefit in Q3. Comments taken from investor presentation slides for Q1 earnings conference call.

06:21 EDT GSK meningococcal ABCWY vaccine candidate accepted for FDA review - GSK plc announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application, or BLA, for its 5-in-1 meningococcal ABCWY vaccine candidate. The Prescription Drug User Fee Act, or PDUFA, goal date for a decision by the US FDA on this application is February 14, 2025.

06:07 EDT Bunge names leadership team for future combination with Viterra - Bunge announced the executive leadership team for the combined Bunge and Viterra business following the close of the proposed transaction. Following the close of the transaction, the combined company will be led by Greg Heckman, Bunge's CEO and John Neppl, Bunge's CFO. Viterra CEO David Mattiske will become Co-COO along with Julio Garros, Bunge's Co-President, Agribusiness. Also serving on the executive leadership team of the future combined company will be Kellie Sears, Chief Human Resources Officer; Joe Podwika, Chief Legal Officer; Robert Wagner, Chief Risk Officer; Pierre Mauger, Chief Transformation Officer; Debra King, Chief Technology Officer; and Robert Coviello, Chief Sustainability Officer and Government Affairs. Other key commercial leaders of the future combined organization include Christos Dimopoulos who assumes the newly created role of EVP, Global Markets. These leadership appointments are effective once the transaction closes, which is anticipated to occur in mid-2024, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals.

06:04 EDT Dick's Sporting, SidelineSwap expand resale partnership - Dick's Sporting and SidelineSwap, the world's largest online marketplace for new and used sporting goods, are expanding their resale partnership for the third straight year to offer SidelineSwap's recommerce services to more DICK'S athletes throughout the U.S. The growth of this partnership comes in direct response to consumers' increased interest in resale to both save money and live more sustainable lifestyles. Throughout 2024, DICK'S athletes will be able to drop-off their used sports gear at SidelineSwap trade-in events at select DICK'S locations throughout the U.S. The used gear will be evaluated by SidelineSwap buying experts, and athletes will be paid with DICK'S e-gift cards to use towards their next purchase. Items that do not qualify for trade-in can be donated or recycled responsibly. DICK'S athletes who attended trade-in events in 2023 received an average payout of $120 for their used gear, and nearly all customers surveyed said they would be interested in reselling their used sports gear at least once per year. Trade-in events in 2024 will be held at DICK'S locations in Pennsylvania, New York, New Jersey, Delaware, Maryland, Virginia, Massachusetts, New Hampshire, Rhode Island, Connecticut, Illinois, Michigan, Colorado, Wisconsin, and Georgia; with additional states potentially to be added.

05:54 EDT Meta to temporarily shut down Threads in Turkey - Meta plans to temporarily shut down Threads in Turkey from April 29 to comply with a Turkish Competition Authority interim order prohibiting data sharing between Threads and Instagram. There is no impact to Facebook, Instagram, WhatsApp or any other Meta services in Turkey, or Threads in other countries, Meta said. Reference Link

05:33 EDT Argenx presents data from ADHERE trial evaluating Vyvgart Hytrulo - Argenx announced that data from its Phase 3 ADHERE trial evaluating Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology, or AAN, annual meeting in Denver, Colorado. Argenx also highlighted clinical trial and real-world data across seven posters and presentations that continue to reinforce Vyvgart and Vyvgart Hytrulo as a transformative treatment option for gMG patients. In the ADHERE study, a majority of patients treated with Vyvgart Hytrulo, regardless of prior treatment, demonstrated evidence of rapid clinical improvement, and a reduced risk of relapse compared to those treated with placebo. As previously reported, ADHERE met its primary endpoint demonstrating a 61% reduction in the risk of relapse versus placebo. Vyvgart Hytrulo was well-tolerated, and the observed safety and tolerability profile was consistent with previous clinical trials. Evidence of rapid onset and maintenance of clinical response: In the open-label Stage A of the ADHERE study, 67% of patients treated with Vyvgart Hytrulo demonstrated evidence of clinical improvement, or ECI, including 40% who had achieved ECI by the earliest possible measure at week 4. In Stage B, Vyvgart Hytrulo-treated patients maintained a clinical response to treatment longer than those on placebo as evidenced by a statistically significant and clinically relevant reduction in risk of relapse. Results across both Stage A and B indicate IgG autoantibodies play a significant role in mediating the underlying biology of CIDP. Overall, 81% of Vyvgart Hytrulo-treated patients demonstrated one point improvement on the aINCAT as compared to baseline Stage A scores in ADHERE, which includes 42% of patients with two-point improvement, 28% with three-point improvement, and 12% with four-point improvement. Clinical benefit was seen across all patient subtypes, including those who had previously received corticosteroids, intravenous or subcutaneous immunoglobulin, or were on no treatment prior to study entry. In total, 99% of eligible patients continued to the ADHERE-Plus open-label extension study. Data from the ADHERE trial were submitted to the FDA as part of a supplemental Biologics License Application, or sBLA, for VYVGART Hytrulo for the treatment of CIDP. The application was accepted for priority review in February and has been granted a PDUFA target action date of June 21.

05:22 EDT Amundi to be combined into Victory Capital in exchange for 26.1% stake - Amundi and Victory Capital announced that they have signed a memorandum of understanding to combine Amundi U.S. into Victory Capital, for Amundi to become a strategic shareholder of Victory Capital, and to establish long-term global distribution agreements. The proposed transaction would create a broader U.S. investment platform for clients of both firms, provide Amundi with access to a wider set of U.S.-managed capabilities, and expand worldwide distribution for Victory Capital. Amundi U.S. currently manages $104B of assets across a broad array of asset classes, including U.S. and global equity, fixed income and multi-asset investment capabilities for individuals and institutions worldwide. Under the proposed transaction: Amundi U.S. would be combined into Victory Capital in exchange for a 26.1% economic stake for Amundi in Victory Capital, with no cash payment involved. Amundi would become a strategic shareholder of Victory Capital with two of its representatives joining the Victory Capital board of directors when the transaction closes. Both parties would simultaneously enter into 15-year reciprocal distribution agreements. Under these proposed distribution agreements: Amundi would be the distributor of Victory Capital's investment offering outside of the U.S. This would allow Victory Capital to further expand its reach beyond the U.S. through Amundi's global client base, which would benefit from Victory Capital's investment expertise and investment performance track record across a wider range of U.S. manufactured solutions. Victory Capital would become the distributor of Amundi's non-U.S. manufactured products in the U.S. As a result, Amundi would gain access to an expanded distribution platform in the U.S., while providing Victory Capital's clients with its wide range of high-performing non-U.S. investment capabilities. As contemplated, the transaction is expected to be accretive for the shareholders of both Victory Capital and Amundi, increasing adjusted net income and earnings per share for both companies. The parties are working toward definitive agreement, which is expected to be announced by the end of the second quarter. The memorandum of understanding is non-binding on the parties. As with any negotiation, there is no certainty that these negotiations will result in a definitive agreement. The ultimate completion of a transaction would remain subject to conditions, including regulatory approvals.